PINCER Platform Study for Solid Organ Cancers to Support High Quality Translational Research

What this Trial Is About

Researchers are conducting a platform study to collect biosamples and related data from patients with solid organ cancers. The study aims to provide an efficient and high-quality source of tumor and blood samples for specific research projects, allowing better understanding of cancer biology. It includes access to both historical tumor tissue and prospective fresh tissue samples, along with matched clinical and radiological data, to create rich datasets for translational research. Participants undergoing biopsy or surgical resection as part of their routine care may provide extra tumor tissue and blood samples. Tissue is collected either during biopsy or surgery with care to ensure pathological assessment is not compromised. Historical tumor tissue blocks may also be accessed and sampled. Blood samples can be taken up to 12 months after treatment. Samples are transported to approved facilities under material transfer agreements and used only for approved sub-studies within the platform. Participants may be asked to complete quality of life questionnaires up to 12 months after treatment. Clinical, pathological, and radiological data will be securely collected and pseudoanonymized for research. Analyses are performed in approved laboratories, and samples may be shared with academic or commercial partners. The study will monitor biosample procurement over four years, with ongoing data collection and participant involvement during this period.

A Platform Study for solId orgaN CancERs